Search - tctmd.com

Displaying 181 - 200 of 257

Sort: Relevancy | Date

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

News Conference News ACC 2020

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

Michael O'Riordan

March 28, 2020

News Daily News

TAVR and Other Advanced CVD Therapies Used Less in Ontario Than NY State

Michael O'Riordan

January 22, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

Deaths After Ablation of Atrial Fibrillation ‘Concerning’ in Real-World Analysis

Michael O'Riordan

October 29, 2019

News Daily News

ARB Use Linked to Suicide in New Study, but Is the Finding Real?

Michael O'Riordan

October 18, 2019

News Daily News

Dramatic Swings in Household Income Linked to CVD Risk: ARIC

Michael O'Riordan

October 09, 2019

News Daily News

Echo Overuse in Heart Failure Stabilizes in the Wake of Ontario Appropriateness Efforts

Michael O'Riordan

August 09, 2019

News Conference News EuroPCR 2019

Clip-Based Tricuspid Repair Improves Regurgitation, Function, and Quality of Life: TRILUMINATE

Michael O'Riordan

May 22, 2019

News Daily News

FDA Warns of Premature Battery Depletion With Certain Medtronic Pacemakers

Michael O'Riordan

May 07, 2019

News Daily News

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

Michael O'Riordan

May 06, 2019

News Daily News

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Michael O'Riordan

May 06, 2019

News Daily News

Mortality From Heart Failure Increasing in United States

Michael O'Riordan

May 06, 2019

News Daily News

Stem Cell Research—Shattered After Fabrication Scandal—Needs to Rebuild, Says EHJ Editor

Michael O'Riordan

April 12, 2019

News Daily News

Younger Type 2 Diabetes Patients Face Higher Mortality and CVD Risks

Michael O'Riordan

April 10, 2019

News Conference News ACC 2019

PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital

Michael O'Riordan

March 25, 2019

News Daily News

One in Two Americans Have Cardiovascular Disease: AHA Stats

Michael O'Riordan

February 04, 2019

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

News Conference News AHA 2018

PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure

Michael O'Riordan

November 11, 2018

Advertisement

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

TAVR and Other Advanced CVD Therapies Used Less in Ontario Than NY State

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Deaths After Ablation of Atrial Fibrillation ‘Concerning’ in Real-World Analysis

ARB Use Linked to Suicide in New Study, but Is the Finding Real?

Dramatic Swings in Household Income Linked to CVD Risk: ARIC

Echo Overuse in Heart Failure Stabilizes in the Wake of Ontario Appropriateness Efforts

Clip-Based Tricuspid Repair Improves Regurgitation, Function, and Quality of Life: TRILUMINATE

FDA Warns of Premature Battery Depletion With Certain Medtronic Pacemakers

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Mortality From Heart Failure Increasing in United States

Stem Cell Research—Shattered After Fabrication Scandal—Needs to Rebuild, Says EHJ Editor

Younger Type 2 Diabetes Patients Face Higher Mortality and CVD Risks

PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital

One in Two Americans Have Cardiovascular Disease: AHA Stats

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content